A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative a...

per Schouten, Philip C., Dackus, Gwen M. H. E., Marchetti, Serena, van Tinteren, Harm, Sonke, Gabe S., Schellens, Jan H. M., Linn, Sabine C.
Publicat a Trials (2016)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer

per Dackus, Gwen M. H. E., Jóźwiak, Katarzyna, van der Wall, Elsken, van Diest, Paul J., Hauptmann, Michael, Siesling, Sabine, Sonke, Gabe S., Linn, Sabine C.
Publicat a Breast Cancer Res Treat (2020)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer

per Geenen, Jill J. J., Dackus, Gwen M. H. E., Schouten, Philip C., Pluim, Dick, Marchetti, Serena, Sonke, Gabe S., Jóźwiak, Katarzyna, Huitema, Alwin D. R., Beijnen, Jos H., Schellens, Jan H. M., Linn, Sabine C.
Publicat a Int J Cancer (2021)

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors

per Droog, Marjolein, Nevedomskaya, Ekaterina, Dackus, Gwen M., Fles, Renske, Kim, Yongsoo, Hollema, Harry, Mourits, Marian J., Nederlof, Petra M., van Boven, Hester H., Linn, Sabine C., van Leeuwen, Flora E., Wessels, Lodewyk F. A., Zwart, Wilbert
Publicat a Proc Natl Acad Sci U S A (2017)